Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Update

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the recipient of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 19,300 shares, a decline of 93.8% from the January 15th total of 311,700 shares. Currently, 1.3% of the company’s shares are short sold. Based on an average daily volume of 1,990,000 shares, the days-to-cover ratio is presently 0.0 days.

Salarius Pharmaceuticals Price Performance

Shares of NASDAQ SLRX traded down $0.05 during mid-day trading on Thursday, hitting $1.66. The company’s stock had a trading volume of 70,337 shares, compared to its average volume of 4,392,980. Salarius Pharmaceuticals has a one year low of $1.22 and a one year high of $7.20. The company’s fifty day simple moving average is $1.94 and its 200-day simple moving average is $1.78. The stock has a market cap of $2.62 million, a price-to-earnings ratio of -0.20 and a beta of 0.84.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.